Table 1.

Baseline and treatment characteristics

Characteristic	Classic	Non-classic	Total
Gender
Male	43	17	60 (61.2%)
Female	25	13	38 (38.8%)
Age
0–10	13	1	14 (14.3%)
11–20	40	9	49 (50.0%)
21–30	10	1	11 (11.2%)
31–40	5	5	10 (10.2%)
41–50	–	4	4 (4.1%)
51–60	–	6	6 (6.1%)
> 60	–	4	4 (4.1%)
Duration of symptoms
≤ 2 months	45	16	61 (62.2%)
> 2 months	23	14	37 (37.8%)
Tumor site
Around knee	46	8	54 (55.1%)
Distal femur	31	4	35 (35.7%)
Proximal tibia	9	3	12 (12.2%)
Proximal fibula	6	1	7 (7.1%)
Proximal humerus	5	1	6 (6.1%)
Other extremities	17	4	21 (21.4%)
Axial	–	17	17 (17.3%)
Tumor size
≤ 8 cm	39	21	60 (61.2%)
> 8 cm	29	9	38 (38.8%)
Primary metastasis
No	68	19	87 (88.8%)
Yes	–	11	11 (11.2%)
Lung	–	9	9 (9.2%)
Distal bones	–	1	1 (1.0%)
Other sites	–	1	1 (1.0%)
Serum ALP			76 available
Normal	20	7	27 (35.5%)
>ULN	38	11	49 (64.5%)
Serum LDH			52 available
Normal	25	12	37 (71.2%)
>ULN	14	1	15 (28.8%)
Type of extremity surgery			81 available
Limb salvage	28	10	38 (46.9%)
Amputation	40	3	43 (53.1%)

ALP alkaline phosphatase, LDH lactate dehydrogenase, ULN upper limit of normal